Apatinib in Refractory Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

June 30, 2019

Study Completion Date

December 30, 2019

Conditions
Colorectal Neoplasms
Interventions
DRUG

apatinib

apatinib 500mg/qd, 28d/cycle

Trial Locations (4)

210000

Nanjing 81 Hospital, Nanjing

210029

the first affiliated hospital with Nanjing Medical University, Nanjing

213000

the second hospital of Changzhou city, Changzhou

214000

Jiangnan University affiliated hospital, Wuxi

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

collaborator

Beijing gene plus technology co., LTD

UNKNOWN

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT03190616 - Apatinib in Refractory Colorectal Cancer | Biotech Hunter | Biotech Hunter